Zinc and Copper Explored for Endometriosis

This study used a multi-faceted approach, starting with systems pharmacology modelling. This is a computational method that integrates information about protein interactions, gene expression, and existing drugs to identify potential new uses for approved medications.

The researchers then narrowed down candidate compounds based on their predicted molecular effectiveness and safety profiles. The most promising candidates were then tested in laboratory cell models.

The computational model identified sixteen potential compounds that appeared to target more endometriosis-related genes than current treatments. After further safety analysis, several compounds were prioritised, including adenine, copper, zinc, NADH, glutathione, and resveratrol.

Of these, zinc, copper, and resveratrol were further investigated in 12Z cells, a type of endometriosis cell model. In these laboratory tests, these compounds appeared to reduce cell proliferation and migration, and decreased the expression of certain endometriosis-related biomarkers.

This initial research suggests that zinc and copper, which are nutraceuticals, may have an effect on endometriosis-related cellular activity in a lab setting. It is important to note that this study involved computational predictions and laboratory cell models, not studies in humans.

The researchers highlight the need for long-term clinical trials to investigate whether these findings translate to similar effects in women with endometriosis. These trials would be crucial to determine the effectiveness and safety of zinc and copper in a real-world context.